NYKD.OL Live signals | Maximize Profits with Getagraph.com

SELL 366 min ago

@ NOK13.27

Issued: 29 Apr 2024 @ 08:52

Return: -0.23%

Previous signal: Apr 29 - 05:49

Previous signal: Buy

Return: 0.30 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 10:25):

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases...

Stats
Today's Volume	774 932
Average Volume	1.08M
Market Cap	4.32B
Next earnings date	( NOK-0.550 ) 2024-05-13
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-10.03
ATR14	NOK0.500 (3.73%)

Volume Correlation

Long: 0.93 (very strong)

Short: -0.17 (neutral)

Signal:(60) Neutral

Nykode Therapeutics AS Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nykode Therapeutics AS Correlation - Currency/Commodity

-0.21
( neutral )

0.61
( weak )

0.00
( neutral )

0.13
( neutral )

-0.20
( neutral )

0.23
( neutral )

Financial Reports:

No articles found.

Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.